Monte S M, Ghanbari K, Frey W H, Beheshti I, Averback P, Hauser S L, Ghanbari H A, Wands J R
MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
J Clin Invest. 1997 Dec 15;100(12):3093-104. doi: 10.1172/JCI119864.
We have isolated a novel Alu sequence-containing cDNA, designated AD7c-NTP, that is expressed in neurons, and overexpressed in brains with Alzheimer's disease (AD). The 1,442-nucleotide AD7c-NTP cDNA encodes an approximately 41-kD protein. Expression of AD7c-NTP was confirmed by nucleic acid sequencing of reverse transcriptase PCR products isolated from brain. AD7c-NTP cDNA probes hybridized with 1. 4 kB mRNA transcripts by Northern blot analysis, and monoclonal antibodies generated with the recombinant protein were immunoreactive with approximately 41-45-kD and approximately 18-21-kD molecules by Western blot analysis. In situ hybridization and immunostaining studies localized AD7c-NTP gene expression in neurons. Using a quantitative enzyme-linked sandwich immunoassay (Ghanbari, K., I. Beheshti, and H. Ghanbari, manuscript submitted for publication) constructed with antibodies to the recombinant protein, AD7c-NTP levels were measured under code in 323 clinical and postmortem cerebrospinal fluid (CSF) samples from AD, age-matched control, Parkinson's disease, and neurological disease control patients. The molecular mass of the AD7c-NTP detected in CSF was approximately 41 kD. In postmortem CSF, the mean concentration of AD7c-NTP in cases of definite AD (9.2+/-8.2 ng/ml) was higher than in the aged control group (1.6+/-0.9; P < 0.0001). In CSF samples from individuals with early possible or probable AD, the mean concentration of AD7c-NTP (4.6+/-3.4) was also elevated relative to the levels in CSF from age-matched (1.2+/-0.7) and neurological disease (1.0+/-0.9) controls, and ambulatory patients with Parkinson's disease (1.8+/-1.1) (all P < 0.001). CSF levels of AD7c-NTP were correlated with Blessed dementia scale scores (r = 0. 66; P = 0.0001) rather than age (r = -0.06; P > 0.1). In vitro studies demonstrated that overexpression of AD7c-NTP in transfected neuronal cells promotes neuritic sprouting and cell death, the two principal neuroanatomical lesions correlated with dementia in AD. The results suggest that abnormal AD7c-NTP expression is associated with AD neurodegeneration, and during the early stages of disease, CSF levels correlate with the severity of dementia.
我们分离出了一种含有新型Alu序列的cDNA,命名为AD7c-NTP,它在神经元中表达,并在阿尔茨海默病(AD)患者的大脑中过表达。1442个核苷酸的AD7c-NTP cDNA编码一种约41kD的蛋白质。从大脑中分离的逆转录酶PCR产物的核酸测序证实了AD7c-NTP的表达。通过Northern印迹分析,AD7c-NTP cDNA探针与1.4kB的mRNA转录本杂交,通过Western印迹分析,用重组蛋白产生的单克隆抗体与约41-45kD和约18-21kD的分子发生免疫反应。原位杂交和免疫染色研究将AD7c-NTP基因表达定位在神经元中。使用针对重组蛋白构建的定量酶联夹心免疫测定法(Ghanbari, K., I. Beheshti, and H. Ghanbari, manuscript submitted for publication),对来自AD患者、年龄匹配的对照、帕金森病患者和神经疾病对照患者的323份临床和死后脑脊液(CSF)样本进行盲法检测,测定AD7c-NTP水平。在脑脊液中检测到的AD7c-NTP的分子量约为41kD。在死后脑脊液中,确诊AD患者的AD7c-NTP平均浓度(9.2±8.2ng/ml)高于老年对照组(1.6±0.9;P<0.0001)。在早期可能或疑似AD患者的脑脊液样本中,AD7c-NTP的平均浓度(4.6±3.4)相对于年龄匹配的对照组(1.2±0.7)、神经疾病对照组(1.0±0.9)以及帕金森病门诊患者(1.8±1.1)的脑脊液水平也有所升高(所有P<0.001)。脑脊液中AD7c-NTP水平与Blessed痴呆量表评分相关(r = 0.66;P = 0.0001),而与年龄无关(r = -0.06;P>0.1)。体外研究表明,在转染的神经元细胞中AD7c-NTP的过表达促进了神经突的萌发和细胞死亡,这是与AD痴呆相关的两个主要神经解剖学病变。结果表明,AD7c-NTP的异常表达与AD神经退行性变有关,并且在疾病的早期阶段,脑脊液水平与痴呆的严重程度相关。